Inflammatory Myofibroblastic Tumor (IMT): Understanding Your Pathology Report

Section Editor: Bibianna Purgina, MD FRCPC
October 12, 2026


Print this article

An inflammatory myofibroblastic tumor, often shortened to IMT, is a rare tumor made of long, thin cells called myofibroblasts, mixed with many immune cells. It can start almost anywhere in the body, but it is most often found in the lungs and in the abdomen and pelvis, including the bladder. It is most common in children and young adults, although it can occur at any age.

Inflammatory myofibroblastic tumor sits between a benign tumor and a cancer. It often recurs in the same place after removal, but it rarely spreads to other parts of the body. Many of these tumors are driven by a change in a gene called ALK, which can be treated with targeted drugs when surgery is not possible.

This article explains how doctors diagnose inflammatory myofibroblastic tumor and what your pathology report says about the tumor type, margins, and gene changes. It also explains what these findings mean for treatment and follow-up.

Who gets inflammatory myofibroblastic tumor?

Inflammatory myofibroblastic tumor can occur at any age, but it is found most often in children, teenagers, and young adults. It is one of the more common tumors of the lung in children. In adults, it most often occurs in the abdomen and pelvis, including the bladder, and in the lungs.

What causes inflammatory myofibroblastic tumor?

The cause of inflammatory myofibroblastic tumor is not fully understood. In most of these tumors, the tumor cells carry a gene change in which part of one gene has joined with part of another gene. This change, called a fusion, makes the cells grow when they should not. The fusion occurs only in tumor cells and is not inherited, so it does not put family members at risk.

The ALK gene is involved in more than half of these tumors. Other genes, such as ROS1, NTRK3, and RET, are involved in smaller numbers. Altogether, modern tests can detect this type of fusion in most inflammatory myofibroblastic tumors.

What are the symptoms of inflammatory myofibroblastic tumor?

The symptoms of inflammatory myofibroblastic tumor depend on where the tumor starts. An abdominal tumor may cause pain, swelling, or a blocked bowel. A lung tumor may cause a cough, chest pain, or shortness of breath. A bladder tumor usually causes blood in the urine.

Some people also have general symptoms, such as fever, weight loss, or tiredness. Blood tests may show anemia or signs of inflammation. These general symptoms often go away after the tumor is removed. Some tumors cause no symptoms and are found on a scan done for another reason.

How is the diagnosis made?

A pathologist diagnoses inflammatory myofibroblastic tumor after examining a tumor sample under a microscope. The sample may be a small biopsy or the whole tumor removed during surgery. Before the biopsy, scans such as CT or MRI are used to see the size of the tumor and whether it has grown into nearby organs.

Under the microscope, inflammatory myofibroblastic tumor consists of spindle cells, long, thin cells with tapering ends. These cells are mixed with many immune cells, especially plasma cells and lymphocytes. The tissue around the cells can look loose and watery (myxoid), or dense and scarred. The tumor cells usually do not look as abnormal as sarcomas

Because inflammatory myofibroblastic tumor can resemble several other tumors and inflammatory conditions, pathologists usually perform additional tests on the tissue. The next section describes these tests.

Immunohistochemistry

Immunohistochemistry uses special stains to show which proteins cells in an inflammatory myofibroblastic tumor make. The results help the pathologist confirm that the cells are myofibroblasts and rule out other tumors that can look similar. The stains used and how results are worded vary between laboratories. Results you may see in your report include:

  • ALK. This stain is positive in about half to two-thirds of these tumors, and it strongly supports the diagnosis. A negative result does not rule out the diagnosis because other genes can drive some tumors. The pattern of ALK staining inside the cell can also help identify the epithelioid type described below.
  • Smooth muscle actin (SMA). This stain is usually positive in the tumor cells. Myofibroblasts make the protein.
  • Desmin. This stain is positive in some tumors and negative in others. The protein is found in muscle cells and in some myofibroblasts.
  • Cytokeratins. This stain may be positive in some of the tumor cells. In this tumor, a positive result does not mean the growth is a carcinoma.

Not every case needs every stain. When the stains do not settle the diagnosis, a molecular test may be performed to look for the gene fusion, as described in the biomarker section below.

What are the different types?

The World Health Organization (WHO) classification of soft tissue tumors, 5th edition (2020), recognizes inflammatory myofibroblastic tumor and a less common type called epithelioid inflammatory myofibroblastic sarcoma. The two types behave very differently, so your report will name the type if it can be determined.

  • Inflammatory myofibroblastic tumor. This is the usual type, made of spindle cells mixed with immune cells. It often recurs in the same place after removal, but it rarely spreads.
  • Epithelioid inflammatory myofibroblastic sarcoma. In this rare type, the tumor cells are round and plump, rather than long and thin. It usually starts in the abdomen and often involves the abdominal lining. ALK stains the edge of the cell nucleus in a ring, and the ALK gene is usually joined to a gene called RANBP2. This type grows quickly, often recurs, and behaves like cancer.

In the urinary tract, a closely related growth called pseudosarcomatous myofibroblastic proliferation is grouped with inflammatory myofibroblastic tumor in the WHO classification of urinary tumors, 5th edition (2022). Your report may use either name for a bladder tumor.

Histologic grade

Inflammatory myofibroblastic tumor is not given a grade. The grading systems used for sarcomas do not predict how this tumor will behave, so your report will not include a grade number, and this is expected. Instead, the tumor type, location, size, and whether it was removed completely provide the most useful information about how it is likely to behave.

Tumor size

The size of an inflammatory myofibroblastic tumor is measured after removal and reported in centimeters. Tumors in the abdomen and pelvis are often larger than tumors in other sites when they are found. Larger tumors are harder to remove completely and more likely to recur. Size measured on a small biopsy does not reflect the size of the whole tumor.

Tumor extension

Inflammatory myofibroblastic tumor can grow into surrounding tissues and organs as it enlarges. This spread into nearby structures is called tumor extension. The pathologist examines all the tissue removed to see whether tumor cells have grown into nearby fat, muscle, or organs. Extension into nearby organs can make complete removal harder and may change the treatment your team recommends.

Margins

When an inflammatory myofibroblastic tumor is removed, the pathologist examines the cut edges of the tissue, called the margins. Because this tumor often grows back in the same place, the margins are one of the most important findings in your report.

  • Negative margin. No tumor cells are seen at the cut edge, which suggests the tumor was completely removed. The distance from the tumor to the nearest margin may also be recorded.
  • Positive margin. Tumor cells are seen at the cut edge, which means some tumor may remain in the body. Your team may recommend closer follow-up, further surgery, or other treatment.

Biomarker and molecular testing

Biomarker testing for inflammatory myofibroblastic tumor looks for the gene fusion that drives tumor growth. Finding the fusion can confirm the diagnosis, and it can make a person eligible for a targeted drug if the tumor cannot be removed or comes back. Clinicians test tumor tissue with fluorescence in situ hybridization (FISH) or next-generation sequencing (NGS).

ALK

ALK is a gene that makes a protein involved in cell growth. In inflammatory myofibroblastic tumor, part of the ALK gene is often joined to another gene, which turns the protein on all the time. ALK fusions are the most common gene change in this tumor.

  • ALK fusion detected. A fusion involving the ALK gene was found. In July 2022, the FDA approved crizotinib, a drug that blocks ALK, for ALK-positive inflammatory myofibroblastic tumors. The approval covers tumors that cannot be removed, have recurred, or have not responded to other treatments. In the studies that led to approval, most children and adults had their tumor shrink.
  • ALK fusion not detected. No ALK fusion was found. Your team may test for the other gene changes described below.

ROS1

ROS1 is a gene that is similar to ALK. A ROS1 fusion is found in a small number of inflammatory myofibroblastic tumors, usually those that are ALK-negative.

  • ROS1 fusion detected. A ROS1 fusion was detected. ROS1-blocking drugs are approved for other cancers and may be considered for this tumor or offered in a clinical trial.
  • ROS1 fusion not detected. No ROS1 fusion was found.

NTRK

The NTRK genes make proteins involved in cell growth. An NTRK3 fusion is found in a small number of inflammatory myofibroblastic tumors.

  • NTRK fusion detected. An NTRK gene fusion was detected. The FDA first approved larotrectinib in November 2018 for advanced solid tumors with an NTRK fusion, regardless of tumor origin. This approval applies to inflammatory myofibroblastic tumor when surgery is not a good option.
  • NTRK fusion not detected. No NTRK fusion was found.

RET

RET is another gene involved in cell growth. A RET fusion is found in only a very small number of inflammatory myofibroblastic tumors.

  • RET fusion detected. A RET fusion was found. In July 2026, the FDA granted full approval of selpercatinib for advanced solid tumors with a RET fusion after earlier treatment, regardless of tumor origin.
  • RET fusion not detected. No RET fusion was found.

Our article on NTRK fusions in cancer explains how fusion testing works. For more information on tumor testing, visit our Biomarkers and Genetic Testing section.

What is the prognosis?

The prognosis for inflammatory myofibroblastic tumor is generally good, especially when the tumor is removed completely. Death from this tumor is uncommon. The main risk is that the tumor grows back in the same place.

  • Growing back. Overall, about 1 in 4 tumors grows back after removal. The risk depends on where the tumor started. It is low for tumors of the lung and bladder, and higher for large tumors of the abdomen and pelvis.
  • Spread. About 5 in 100 inflammatory myofibroblastic tumors spread to other parts of the body, and about 95 in 100 do not.
  • Epithelioid inflammatory myofibroblastic sarcoma. This type has a much less favorable outlook. It often grows back quickly and can be life-threatening.

These numbers are averages for large groups of people and don’t predict what will happen to you. Features in your report that are linked to a higher chance of the tumor growing back or spreading include:

  • A positive margin. Tumor cells at the cut edge of the tissue removed.
  • A large tumor. Especially a tumor in the abdomen or pelvis.
  • Extension into nearby organs. A tumor that has grown into surrounding structures.
  • The epithelioid type. Round tumor cells with a ring-like ALK stain and a RANBP2::ALK fusion.

What happens after the diagnosis?

After a diagnosis of inflammatory myofibroblastic tumor, your care team uses the type of tumor, the margins, and other findings in your report to plan treatment. The team may include a surgeon, a medical oncologist, and, for children, a pediatric oncologist. Treatment depends mainly on whether the whole tumor can be removed safely.

  • Surgery. Complete removal of the tumor with negative margins is the main treatment, and it is often the only treatment needed.
  • ALK-targeted treatment. For an ALK-positive tumor that cannot be removed, has come back, or has not responded, crizotinib may be used. It is sometimes given before surgery to shrink a large tumor.
  • Other targeted treatment. For tumors with an NTRK or RET fusion, the matching tumor-agnostic drugs described in the biomarker section may be options.
  • Other medicines. When targeted drugs are not suitable, steroids, anti-inflammatory drugs, or chemotherapy are sometimes used.
  • Follow-up. Because the tumor can grow back, doctors usually do regular scans of the area for several years after treatment.

Approval and access to these drugs differ by country, and your care team can explain what applies where you live.

Questions to ask your doctor

  • Is my tumor the usual type of inflammatory myofibroblastic tumor, or the epithelioid type?
  • Was the ALK stain positive or negative?
  • Was a gene fusion test done, and which gene was involved?
  • How large was the tumor, and did it grow into nearby organs?
  • Were the margins negative, and how close was the tumor to the nearest margin?
  • Was the whole tumor removed?
  • Do I need treatment after surgery?
  • Would a targeted drug such as crizotinib be an option if the tumor grows back?
  • What is the chance that the tumor will grow back in my case?
  • How often will I need scans, and for how long?
  • Should I be referred to a center with experience in this rare tumor?

Related articles on MyPathologyReport.com

A+ A A-
Was this article helpful?